Guardian Pharmacy Services (GRDN)


Market Price (11/17/2026): $49.39 | Market Cap: $3.1 BilSector: Health Care | Industry: Health Care Facilities

Guardian Pharmacy Services (GRDN)


Market Price (11/17/2026): $49.39
Market Cap: $3.1 Bil
Sector: Health Care
Industry: Health Care Facilities

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Low stock price volatility
Vol 12M is 43%

Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Health Data Analytics, Show more.

Trading close to highs
Dist 52W High is -1.1%, Dist 3Y High is -1.1%

Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 30x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 28x, P/EPrice/Earnings or Price/(Net Income) is 42x

Weak revenue growth
Rev Chg QQuarterly Revenue Change % is -1.7%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.7%

Key risks
GRDN key risks include [1] margin compression from inflation due to its inability to raise prices for customers whose reimbursements are dictated by the government and PBMs, Show more.

0 Low stock price volatility
Vol 12M is 43%
1 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Health Data Analytics, Show more.
2 Trading close to highs
Dist 52W High is -1.1%, Dist 3Y High is -1.1%
3 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 30x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 28x, P/EPrice/Earnings or Price/(Net Income) is 42x
4 Weak revenue growth
Rev Chg QQuarterly Revenue Change % is -1.7%
5 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.7%
6 Key risks
GRDN key risks include [1] margin compression from inflation due to its inability to raise prices for customers whose reimbursements are dictated by the government and PBMs, Show more.

GRDN in ETFs

Weight = GRDN's share of each fund

VTI0.00%
ITOT0.00%
IWM0.05%
IWO0.09%
VTWO0.04%
SCHA0.04%
DFAS0.03%
VHT0.02%
+3 more covered ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/16/2026

Nov 10: up 6.0% in one day (S&P 500 down 0.4%)
The stock rose significantly without company news. The market moved downward that day.

Up 28.2% from its Oct 21 low to Nov 11 (S&P 500 down 1.7%)
The run was largely driven by positive third quarter earnings results and other periods of upward movement without specific company news. The largest daily gains occurred on November 9 and on November 6 following the earnings report.

Nov 6: up 6.3% the day after its Nov 5 earnings report (S&P 500 up 0.3%)
The stock gained after third quarter earnings of $0.33 per share beat the Zacks Consensus Estimate of $0.32 per share. Net income rose 90% and diluted EPS increased 93% compared to a year earlier.

Show more
Prices as of 11/16/2026

Nov 10: up 6.0% in one day (S&P 500 down 0.4%)
The stock rose significantly without company news. The market moved downward that day.

Up 28.2% from its Oct 21 low to Nov 11 (S&P 500 down 1.7%)
The run was largely driven by positive third quarter earnings results and other periods of upward movement without specific company news. The largest daily gains occurred on November 9 and on November 6 following the earnings report.

Nov 6: up 6.3% the day after its Nov 5 earnings report (S&P 500 up 0.3%)
The stock gained after third quarter earnings of $0.33 per share beat the Zacks Consensus Estimate of $0.32 per share. Net income rose 90% and diluted EPS increased 93% compared to a year earlier.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 25.0% change in GRDN stock from 7/31/2026 to 11/16/2026 was primarily driven by a 40.8% change in the company's Net Income Margin (%).
(LTM values as of)731202611162026Change
Stock Price ($)39.5349.4325.0%
Change Contribution By: 
Total Revenues ($ Mil)1,4561,4570.1%
Net Income Margin (%)3.6%5.1%40.8%
P/E Multiple47.242.3-10.4%
Shares Outstanding (Mil)6364-0.9%
Cumulative Contribution25.0%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/16/2026
ReturnCorrelation
GRDN25.0% 
Market (SPY)-0.7%24.3%
Sector (XLV)16.0%19.7%

Fundamental Drivers

The 33.2% change in GRDN stock from 4/30/2026 to 11/16/2026 was primarily driven by a 51.0% change in the company's Net Income Margin (%).
(LTM values as of)430202611162026Change
Stock Price ($)37.1049.4333.2%
Change Contribution By: 
Total Revenues ($ Mil)1,4491,4570.6%
Net Income Margin (%)3.4%5.1%51.0%
P/E Multiple45.242.3-6.6%
Shares Outstanding (Mil)6064-6.1%
Cumulative Contribution33.2%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/16/2026
ReturnCorrelation
GRDN33.2% 
Market (SPY)3.5%18.3%
Sector (XLV)29.8%20.4%

Fundamental Drivers

The 76.3% change in GRDN stock from 10/31/2025 to 11/16/2026 was primarily driven by a 65.3% change in the company's P/S Multiple.
(LTM values as of)1031202511162026Change
Stock Price ($)28.0449.4376.3%
Change Contribution By: 
Total Revenues ($ Mil)1,3271,4579.8%
P/S Multiple1.32.265.3%
Shares Outstanding (Mil)6264-2.9%
Cumulative Contribution76.3%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/16/2026
ReturnCorrelation
GRDN76.3% 
Market (SPY)9.7%23.4%
Sector (XLV)32.4%23.6%

Fundamental Drivers

null
null

Market Drivers

10/31/2023 to 11/16/2026
ReturnCorrelation
GRDN  
Market (SPY)83.5%25.3%
Sector (XLV)58.6%24.5%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
GRDN Return---27%49%64%209%
Peers Return26%8%12%-1%20%57%184%
S&P 500 Return27%-19%24%23%16%10%101%

Monthly Win Rates [3]
GRDN Win Rate---75%67%64% 
Peers Win Rate62%52%58%46%56%62% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
GRDN Max Drawdown-----26%-19% 
Peers Max Drawdown-18%-41%-30%-39%-35%-31% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: ACHC, INNV, STLN, HCA, THC.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/16/2026 (YTD)

How Low Can It Go

EventGRDNS&P 500
2025 US Tariff Shock
  % Loss-12.4%-18.8%
  % Gain to Breakeven14.1%23.1%
  Time to Breakeven12 days79 days

Compare to ACHC, INNV, STLN, HCA, THC

In The Past

Guardian Pharmacy Services's stock fell -12.4% during the 2025 US Tariff Shock. Such a loss loss requires a 14.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

null

Compare to ACHC, INNV, STLN, HCA, THC

In The Past

Guardian Pharmacy Services's stock fell -12.4% during the 2025 US Tariff Shock. Such a loss loss requires a 14.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Guardian Pharmacy Services (GRDN)

Guardian Pharmacy Services (GRDN) is a leading pharmacy services company specializing in providing technology-enabled solutions to long-term health care facilities (LTCFs). Its core mission is to help residents of these facilities adhere to their appropriate drug regimens, which ultimately reduces healthcare costs and improves clinical outcomes. The company focuses on delivering high-touch, individualized drug dispensing and administration services, particularly tailored for historically lower acuity LTCFs such as assisted living facilities (ALFs) and behavioral health facilities and group homes (BHFs). These target markets represent over two-thirds of GRDN’s annual revenue, though it also serves skilled nursing facilities (SNFs).

GRDN differentiates itself by addressing the specific challenges faced by ALFs and BHFs, including residents having diverse pharmacy benefit plans, facilities often lacking on-site clinical staff, and residents' right to choose their pharmacy. As a trusted partner to residents, LTCFs, and health plan payors, Guardian offers an extensive suite of services. These include optimizing pharmacy benefit plan coverage, analyzing potential adverse drug interactions, providing robotic dispensing with customized compliance solutions, and integrating drug regimens with facilities' Electronic Medication Administration Records (EMARs). The company also trains LTCF caregivers, conducts compliance mock audits, and employs consulting pharmacists to periodically review resident drug regimens, all supported by proprietary data analytics systems to ensure precise medication delivery.

AI Analysis | Feedback

Here are 1-3 brief analogies to describe Guardian Pharmacy Services (GRDN):

  • ADP for medication management in assisted living facilities.
  • Salesforce for medication management in assisted living facilities.
  • PillPack by Amazon Pharmacy for assisted living facilities.

AI Analysis | Feedback

  • Medication Dispensing and Adherence Solutions: Provides robotic dispensing and customized medication packaging, integrated with Electronic Medication Administration Records (EMARs), to ensure residents receive their prescribed drugs accurately and on time.
  • Clinical Pharmacy Consulting Services: Offers expert consultation including proactive analysis of potential adverse drug interactions and periodic review of resident drug regimens by consulting pharmacists.
  • Pharmacy Benefit Plan Optimization: Assists residents in optimizing their pharmacy benefit plan coverage by coordinating formulary interchanges with their physicians.
  • Caregiver Training and Education: Delivers training to long-term care facility caregivers to enhance their ability to administer medications safely, efficiently, and cost-effectively.
  • Regulatory Compliance Support: Conducts mock audits for long-term care facilities to help monitor and ensure compliance with drug administration and government regulations.

AI Analysis | Feedback

Guardian Pharmacy Services (GRDN) sells primarily to individuals.

The company serves the following categories of customers:

  • Residents of Assisted Living Facilities (ALFs)
  • Residents of Behavioral Health Facilities and Group Homes (BHFs)
  • Residents of Skilled Nursing Facilities (SNFs)

AI Analysis | Feedback

null

AI Analysis | Feedback

Fred Burke President & CEO

Fred Burke is the President, CEO, and Co-founder of Guardian Pharmacy Services, which he founded in 2004. Prior to Guardian, he co-founded Central Pharmacy Services, Inc. (CPSI) in 1992, a nuclear pharmacy company that grew to 45 business units and served over 1,000 hospitals and clinics across 22 states. CPSI was recognized on the Inc. 500 lists in 1997 and 1999, and was subsequently acquired by Cardinal Health in 2001. Burke also co-founded Sales Technologies, Inc. (ST) in 1983, a sales force automation company that achieved over 600 employees worldwide before its acquisition by The Dun & Bradstreet Corporation in 1989. His early career includes roles as a consultant with McKinsey & Company and a Brand Manager at Procter & Gamble. Guardian Pharmacy Services has been primarily capitalized by Bindley Capital Partners, LLC, and Cardinal Equity Partners has also made significant capital investments, indicating a pattern of managing companies backed by private equity firms.

David Morris EVP & CFO

David Morris is the EVP and CFO, and a Co-founder of Guardian Pharmacy Services. He served as CFO of Central Pharmacy Services (CPSI) from 1993 to 2001, joining shortly after its inception to build the central support and financial structure, and was part of the team when CPSI was acquired by Cardinal Health. Before that, Morris was the President of the PBM Division at Complete Health and worked as a Certified Public Accountant at Ernst & Young LLP. Guardian Pharmacy Services has been primarily capitalized by Bindley Capital Partners, LLC, and Cardinal Equity Partners has also made significant capital investments, indicating a pattern of managing companies backed by private equity firms.

Kendall Forbes EVP, Sales & Operations

Kendall Forbes is a Co-founder and EVP of Sales & Operations at Guardian Pharmacy Services. With over 35 years of experience, he played a key role in the growth of Guardian and its pharmacy partners. Prior to co-founding Guardian, Forbes was a co-founder and the Executive Vice President of Operations for Central Pharmacy Services (CPSI) from 1993 to 2004, which was acquired by Cardinal Health. He also previously owned Baton Rouge Central Pharmacy from 1985 to 1993. Guardian Pharmacy Services has been primarily capitalized by Bindley Capital Partners, LLC, and Cardinal Equity Partners has also made significant capital investments, indicating a pattern of managing companies backed by private equity firms.

AI Analysis | Feedback

1. Intense Competition and Resident Choice

Guardian Pharmacy Services operates in a highly competitive environment where residents in Assisted Living Facilities (ALFs) have the right to choose their own pharmacy. This often leads to multiple pharmacy service providers within a single ALF, requiring Guardian to continuously strive for "resident adoption" to acquire and retain customers, posing a risk of losing residents to competitors. [cite: background]

2. Reliance on Complex and Evolving Reimbursement Structures

The company navigates a complex landscape of varying pharmacy benefit plans, each with distinct formularies and reimbursement processes. Changes in these plans, formularies, or overall reimbursement policies by health plan payors could significantly impact Guardian's revenue and profitability. [cite: background]

3. Concentration in Assisted Living and Behavioral Health Markets

Over two-thirds of Guardian's annual revenue is generated from residents of Assisted Living Facilities (ALFs) and Behavioral Health Facilities (BHFs). This high concentration means the business is particularly vulnerable to adverse trends, regulatory changes, or shifts in growth potential within these specific long-term care sectors. [cite: background]

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

Guardian Pharmacy Services (GRDN) is expected to drive future revenue growth over the next 2-3 years through several key strategies: * Growth in Resident Count: The company anticipates continued expansion in its total resident count, driven by both organic growth and strategic acquisitions. In the fourth quarter of 2025, Guardian Pharmacy Services reported serving over 205,000 residents, a 10% increase year-over-year, with total resident count increasing by 13% year-over-year in Q3 2025. This growth in the number of residents directly contributes to higher revenue. * Increased Script Volume and Higher Acuity Services: Revenue growth is also expected from an increase in script volume, indicating both higher resident utilization and an expanding need for pharmacy services. Script volume grew 14% year-over-year in Q4 2025, reflecting broader resident and utilization expansion. Furthermore, the company notes that organic revenue growth is driven by new resident additions, script growth, and higher acuity residents, suggesting that serving more complex patient needs also contributes to increased revenue per resident. * Geographic Expansion via Greenfield Development and Strategic Acquisitions: Guardian Pharmacy Services is actively expanding its footprint into new regions through a combination of greenfield investments (new pharmacy startups) and strategic acquisitions. Recent acquisitions in areas like the Pacific Northwest have expanded the company's operational presence and are contributing to overall growth. * Enhanced Resident Adoption in Existing Facilities: The company focuses on partnering with long-term care facility operators to increase the number of residents utilizing Guardian's services within each facility. This "resident adoption" strategy aims to streamline drug administration and minimize medication management risks, thereby increasing service penetration and revenue from existing partnerships.

AI Analysis | Feedback

Share Repurchases

  • Guardian Pharmacy Services announced a plan in May 2025 to buy back 1,457,365 shares in a private transaction, utilizing proceeds from a public offering.
  • In 2025, the company completed a "synthetic secondary" transaction, repurchasing 1,440,447 outstanding shares of Class A Common Stock at $21.00 per share, amounting to approximately $30.25 million.
  • The 2025 financial results reported repurchases of outstanding Class A common stock totaling $29.039 million.

Share Issuance

  • Guardian Pharmacy Services, Inc. completed its Initial Public Offering (IPO) on September 25, 2024, issuing 8,000,000 shares of Class A common stock at $14.00 per share, raising $112 million.
  • In May 2025, as part of a non-dilutive "synthetic secondary" transaction, the company issued 1,440,447 new shares of Class A common stock, with the net proceeds used to repurchase an equal number of shares.
  • Following the IPO, the company anticipated granting equity awards, including stock options with an aggregate award value of $10.0 million and restricted stock units valued at $9.0 million starting in 2025.

Inbound Investments

  • Prior to its IPO, Cardinal Equity Partners, along with founders Fred Burke, David Morris, and Kendall Forbes, made significant capital investments in Guardian.
  • As of December 31, 2025, Brown Advisory Inc and its affiliated entities reported a 4.54% beneficial ownership stake in Guardian Pharmacy Services, comprising 1,644,569 shares of Class A common stock.

Outbound Investments

  • In the first quarter of 2025, Guardian Pharmacy Services acquired Senior Care Pharmacy in Wichita, Kansas, as part of its growth strategy.
  • During the fourth quarter of 2025, the company acquired North Ridge Pharmacy in Missoula, Montana, increasing its total number of full-service pharmacies to 54.

Capital Expenditures

  • Guardian Pharmacy Services has demonstrated significant reinvestment in its business, with its return on capital employed increasing to 27% over the last five years and 82% more capital being utilized.
  • The company's financial reporting indicates that Adjusted EBITDA does not account for cash capital expenditure requirements related to asset replacements or new capital investments, suggesting ongoing capital expenditure needs for operational maintenance and growth.
  • While specific dollar values for general capital expenditures are not detailed in available reports, the acquisitions of Senior Care Pharmacy in Q1 2025 and North Ridge Pharmacy in Q4 2025 represent significant capital deployment for expanding its pharmacy network.

Better Bets vs. Guardian Pharmacy Services (GRDN)

Peer Outperformance in Health Care Facilities

null
Share of Health Care Facilities constituents that GRDN has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
80%
of 30 industry peers · 69.2% return
3Y
—
insufficient peer history
5Y
—
insufficient peer history
null
Median price return by industry across the Health Care sector, ranked by 5Y. Health Care Facilities is GRDN's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 6 9.2%55.6%107.4% CAH 528% · MCK 413% · COR 206%
Health Care Services 20 32.4%20.7%15.7% RDNT 149% · HIMS 127% · DGX 95%
Managed Health Care 8 83.3%2.2%4.8% OSCR 163% · HQY 55% · ELV 12%
Health Care Facilities ← 26 13.2%19.7%-7.0% THC 266% · NHC 228% · EHC 198%
Health Care Equipment 49 1.6%7.4%-19.7% GKOS 389% · UFPT 341% · TMDX 273%
Health Care Supplies 11 23.9%2.5%-40.4% LNTH 245% · HAE 104% · MMSI 25%
Pharmaceuticals 61 -19.4%0.5%-43.2% LQDA 1072% · KNSA 632% · XERS 599%
Life Sciences Tools & Services 110 -23.2%-25.7%-76.3% AXGN 370% · MEDP 188% · NTRA 151%
Health Care Technology 23 -24.1%-58.7%-82.7% VEEV -6% · DOCS -52%
Biotechnology 370 -33.7%-37.9%-84.0% ELVN 1354% · TRVI 1154% · DNTH 1140%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

GRDNACHCINNVSTLNHCATHCMedian
NameGuardian.Acadia H.InnovAge Starling.HCA Heal.Tenet He. 
Mkt Price49.3938.699.593.53511.50291.5444.04
Mkt Cap3.23.51.30.4109.823.43.3
Rev LTM1,4573,4111,01862078,70123,6262,434
Op Inc LTM9433318-2112,0525,321214
FCF LTM96-2476195,9733,32886
FCF 3Y Avg67-28931-166,6502,40849
CFO LTM114235902311,1694,238175
CFO 3Y Avg8423341-1211,5453,306159

Growth & Margins

GRDNACHCINNVSTLNHCATHCMedian
NameGuardian.Acadia H.InnovAge Starling.HCA Heal.Tenet He. 
Rev Chg LTM4.9%4.5%15.1%34.6%5.8%13.3%9.6%
Rev Chg 3Y Avg14.0%6.1%13.4%26.2%7.6%5.6%10.5%
Rev Chg Q-1.7%5.1%12.1%24.3%3.6%18.7%8.6%
QoQ Delta Rev Chg LTM-0.4%1.3%2.9%5.7%0.9%4.4%2.1%
Op Inc Chg LTM60.4%-24.9%713.8%48.9%3.6%59.0%53.9%
Op Inc Chg 3Y Avg-39.4%-11.4%285.8%26.1%9.3%32.8%17.7%
Op Mgn LTM6.5%9.8%1.7%-3.4%15.3%22.5%8.1%
Op Mgn 3Y Avg1.7%13.6%-0.3%-9.7%15.3%17.4%7.7%
QoQ Delta Op Mgn LTM0.6%-0.3%1.1%1.1%-0.2%3.0%0.8%
CFO/Rev LTM7.8%6.9%8.8%3.7%14.2%17.9%8.3%
CFO/Rev 3Y Avg6.1%7.1%4.1%-3.5%15.6%15.0%6.6%
FCF/Rev LTM6.6%-0.7%7.5%3.0%7.6%14.1%7.0%
FCF/Rev 3Y Avg4.8%-9.1%3.0%-4.3%9.0%10.9%3.9%

Valuation

GRDNACHCINNVSTLNHCATHCMedian
NameGuardian.Acadia H.InnovAge Starling.HCA Heal.Tenet He. 
Mkt Cap3.23.51.30.4109.823.43.3
P/S2.21.01.30.61.41.01.2
P/Op Inc33.510.574.6-17.69.14.49.8
P/EBIT29.8-3.884.3-14.79.04.26.6
P/E42.2-3.1145.3-10.416.28.112.1
P/CFO27.715.014.616.09.85.514.8
Total Yield2.4%-32.1%0.7%-9.6%6.8%12.4%1.5%
Dividend Yield0.0%0.0%0.0%0.0%0.6%0.0%0.0%
FCF Yield 3Y Avg3.7%-8.3%3.1%-6.8%13.2%3.7%
D/E0.00.70.10.30.50.60.4
Net D/E-0.00.7-0.10.20.50.50.3

Returns

GRDNACHCINNVSTLNHCATHCMedian
NameGuardian.Acadia H.InnovAge Starling.HCA Heal.Tenet He. 
1M Rtn25.1%29.1%8.3%-45.1%11.5%9.1%10.3%
3M Rtn30.0%29.0%-10.2%-44.1%26.5%10.2%18.4%
6M Rtn37.9%52.9%32.2%-31.7%21.4%51.5%35.0%
12M Rtn69.1%141.5%98.0%-31.7%9.0%51.1%60.1%
3Y Rtn208.7%-46.8%67.6%-31.7%112.4%357.4%90.0%
1M Excs Rtn26.4%30.3%9.6%-43.8%12.8%10.4%11.6%
3M Excs Rtn30.7%42.6%-12.0%-43.2%26.2%9.6%17.9%
6M Excs Rtn35.7%50.7%30.1%-33.9%19.3%49.3%32.9%
12M Excs Rtn50.1%128.4%66.6%-43.9%-3.4%36.0%43.1%
3Y Excs Rtn134.8%-120.4%1.9%-105.5%56.1%379.7%29.0%

Comparison Analyses

null

FDA Approved Drugs Data

Expand for More
Post-Approval Fwd Returns
FDA
App #
Brand
Name
Generic
Name
Dosage
Form
FDA
Approval
3M
Rtn
6M
Rtn
1Y
Rtn
2Y
Rtn
Total
Rtn
ANDA216149  ESOMEPRAZOLE MAGNESIUMesomeprazole magnesiumcapsule, delayed release3152023     
ANDA214541  LOPERAMIDE HYDROCHLORIDE AND SIMETHICONEloperamide hydrochloridetablet5272021     
ANDA210755  IBUPROFENibuprofensuspension/drops9262018     
ANDA210149  IBUPROFENibuprofensuspension8172018     
ANDA209215  GUAIFENESINguaifenesintablet, extended release9062017     
Collapse to Preview
Post-Approval Fwd Returns
FDA
App #
Brand
Name
Generic
Name
Dosage
Form
FDA
Approval
3M
Rtn
6M
Rtn
1Y
Rtn
2Y
Rtn
Total
Rtn
ANDA216149  ESOMEPRAZOLE MAGNESIUMesomeprazole magnesiumcapsule, delayed release3152023     
ANDA214541  LOPERAMIDE HYDROCHLORIDE AND SIMETHICONEloperamide hydrochloridetablet5272021     
ANDA210755  IBUPROFENibuprofensuspension/drops9262018     
ANDA210149  IBUPROFENibuprofensuspension8172018     
ANDA209215  GUAIFENESINguaifenesintablet, extended release9062017     

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Sales of pharmaceutical and medical products1,4491,2281,046909792
Total1,4491,2281,046909792


Net Income by Segment
$ Mil202520242023
Sales of pharmaceutical and medical products49-7138
Total49-7138


Price Behavior

Price Behavior
Market Price$49.43 
Market Cap ($ Bil)3.2 
First Trading Date09/26/2024 
Distance from 52W High-1.1% 
   50 Days200 Days
DMA Price$42.65$38.95
DMA Trendupup
Distance from DMA15.9%26.9%
 3M1YR
Volatility45.7%42.9%
Downside Capture-47.4662.78
Upside Capture83.14110.85
Correlation (S&P 500)23.4%23.3%
GRDN Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta-0.50-0.85-0.170.080.53-0.06
Up Beta-1.02-1.26-0.01-0.560.050.12
Down Beta-1.42-1.12-1.84-0.470.030.02
Up Capture-16%-38%27%48%105%48%
Bmk +ve Days12182862130427
Stock +ve Days11222861129277
Down Capture-12%-124%14%40%77%78%
Bmk -ve Days10253664121325
Stock -ve Days11213665122246

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with GRDN
GRDN62.8%42.9%1.24-
Sector ETF (XLV)25.2%16.8%1.1522.3%
Equity (SPY)11.3%13.7%0.5221.8%
Gold (GLD)-7.8%28.9%-0.296.0%
Commodities (DBC)32.1%21.3%1.20-14.0%
Real Estate (VNQ)11.8%14.1%0.5410.4%
Bitcoin (BTCUSD)-31.6%43.8%-0.757.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with GRDN
GRDN25.1%47.6%1.26-
Sector ETF (XLV)8.8%15.4%0.3724.5%
Equity (SPY)11.0%17.3%0.4725.3%
Gold (GLD)15.7%19.2%0.652.8%
Commodities (DBC)7.3%19.6%0.26-10.2%
Real Estate (VNQ)1.2%18.9%-0.0420.1%
Bitcoin (BTCUSD)0.2%51.4%0.195.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with GRDN
GRDN11.9%47.6%1.26-
Sector ETF (XLV)12.9%16.8%0.6324.5%
Equity (SPY)15.3%18.0%0.7225.3%
Gold (GLD)11.0%16.6%0.542.8%
Commodities (DBC)7.5%18.2%0.33-10.2%
Real Estate (VNQ)6.2%20.7%0.2520.1%
Bitcoin (BTCUSD)58.0%66.2%0.985.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity2.2 Mil
Short Interest: % Change Since 10152026-7.5%
Average Daily Volume0.3 Mil
Days-to-Cover Short Interest6.6 days
Basic Shares Quantity63.9 Mil
Short % of Basic Shares3.4%

Earnings Returns History

Updated 11/16/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/5/20266.3%23.9% 
8/6/202611.0%-2.6%3.3%
5/6/2026-0.8%-2.5%10.7%
3/11/2026-0.7%1.2%16.8%
1/13/2026-3.6%-6.1%6.0%
11/10/20255.0%-4.8%4.8%
8/11/202513.8%24.8%45.8%
5/12/2025-4.0%3.4%-21.4%
...
SUMMARY STATS   
# Positive558
# Negative551
Median Positive6.3%6.4%12.1%
Median Negative-3.6%-2.8%-21.4%
Max Positive13.8%24.8%45.8%
Max Negative-10.7%-6.1%-21.4%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/5/20266.3%23.9% 
8/6/202611.0%-2.6%3.3%
5/6/2026-0.8%-2.5%10.7%
3/11/2026-0.7%1.2%16.8%
1/13/2026-3.6%-6.1%6.0%
11/10/20255.0%-4.8%4.8%
8/11/202513.8%24.8%45.8%
5/12/2025-4.0%3.4%-21.4%
3/26/20254.3%6.4%19.6%
11/12/2024-10.7%-2.8%13.5%
SUMMARY STATS   
# Positive558
# Negative551
Median Positive6.3%6.4%12.1%
Median Negative-3.6%-2.8%-21.4%
Max Positive13.8%24.8%45.8%
Max Negative-10.7%-6.1%-21.4%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/05/202610-Q
06/30/202608/06/202610-Q
03/31/202605/06/202610-Q
12/31/202503/11/202610-K
09/30/202511/10/202510-Q
06/30/202508/11/202510-Q
03/31/202505/12/202510-Q
12/31/202403/26/202510-K
09/30/202411/12/202410-Q
06/30/202409/16/2024424A
06/30/202310/03/2023S-1
03/31/202307/12/2023DRS/A
09/30/202111/22/2021DRS/A
03/31/202107/23/2021DRS/A
12/31/201904/03/2020DRS/A
09/30/201902/13/2020DRS
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/05/202610-Q
06/30/202608/06/202610-Q
03/31/202605/06/202610-Q
12/31/202503/11/202610-K
09/30/202511/10/202510-Q
06/30/202508/11/202510-Q
03/31/202505/12/202510-Q
12/31/202403/26/202510-K
09/30/202411/12/202410-Q
06/30/202409/16/2024424A
06/30/202310/03/2023S-1
03/31/202307/12/2023DRS/A
09/30/202111/22/2021DRS/A
03/31/202107/23/2021DRS/A
12/31/201904/03/2020DRS/A
09/30/201902/13/2020DRS

Recent Forward Guidance

Updated 11/6/2026

Latest: Q3 2026 Earnings Reported 11/5/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported1.44 Bil1.45 Bil1.46 Bil0.7% RaisedGuidance: 1.44 Bil for 2026
2026 Adjusted EBITDAReported136.00 Mil137.00 Mil138.00 Mil5.4% RaisedGuidance: 130.00 Mil for 2026


Prior: Q2 2026 Earnings Reported 8/6/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported1.43 Bil1.44 Bil1.45 Bil2.1% RaisedGuidance: 1.41 Bil for 2026
2026 Adjusted EBITDAReported129.00 Mil130.00 Mil131.00 Mil4.0% RaisedGuidance: 125.00 Mil for 2026

Q1 2026 Earnings Reported 5/6/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported1.40 Bil1.41 Bil1.42 Bil0 AffirmedGuidance: 1.41 Bil for 2026
2026 Adjusted EBITDAReported123.00 Mil125.00 Mil127.00 Mil2.5% RaisedGuidance: 122.00 Mil for 2026

Q4 2025 Earnings Reported 3/11/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported1.40 Bil1.41 Bil1.42 Bil0 AffirmedGuidance: 1.41 Bil for 2026
2026 Adjusted EBITDAReported120.00 Mil122.00 Mil124.00 Mil4.7% RaisedGuidance: 116.50 Mil for 2026

Insider Activity

Updated 4/26/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Pharmacy, Investors, Llc DirectSell324202629.68827,63624,566,30630,748,933Form
2Morris, David KSee RemarksDirectSell324202629.68187,8555,576,0067,553,365Form
3Burke, FredSee RemarksDirectSell324202629.68671,43219,929,78024,945,559Form
4Forbes, KendallSee RemarksDirectSell324202629.68346,67210,290,09213,453,771Form
5Cardinal, Equity Fund, LP DirectSell324202629.68275,7288,184,29610,244,113Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Pharmacy, Investors, Llc DirectSell324202629.68827,63624,566,30630,748,933Form
2Morris, David KSee RemarksDirectSell324202629.68187,8555,576,0067,553,365Form
3Burke, FredSee RemarksDirectSell324202629.68671,43219,929,78024,945,559Form
4Forbes, KendallSee RemarksDirectSell324202629.68346,67210,290,09213,453,771Form
5Cardinal, Equity Fund, LP DirectSell324202629.68275,7288,184,29610,244,113Form
6Salentine, Thomas J JR Bindley Capital Partners I, LLCSell324202629.683,570,677105,986,620132,660,472Form
7Bindley, Capital Partners I, Llc DirectSell324202629.683,570,677105,986,620132,660,472Form
8Ackerman, John Pharmacy Investors, LLCSell324202629.68827,63624,566,30630,748,933Form
9Ackerman, John Cardinal Equity Fund, L.P.Sell324202629.68275,7288,184,29610,244,113Form
10Bindley, William E Bindley Capital Partners I, LLCSell324202629.683,570,677105,986,620132,660,472Form
11Cosler, Steven D DirectBuy1205202529.613,37099,786739,776Form
12Cardinal, Equity Fund, LP DirectSell930202520.1650,3051,014,1493,019,847Form
13Pharmacy, Investors, Llc DirectSell930202520.16150,9983,044,1209,064,420Form
14Cardinal, Equity Fund, LP DirectSell930202520.16270,9585,462,5134,033,996Form
15Pharmacy, Investors, Llc DirectSell930202520.16813,31816,396,49112,108,540Form
16Bindley, William E Bindley Capital Partners I, LLCSell529202520.16651,45413,133,31339,106,711Form
17Salentine, Thomas J JR Bindley Capital Partners I, LLCSell529202520.16651,45413,133,31339,106,711Form
18Ackerman, John Pharmacy Investors, LLCSell529202520.16150,9983,044,1209,064,420Form
19Ackerman, John Cardinal Equity Fund, L.P.Sell529202520.1650,3051,014,1493,019,847Form
20Morris, David KSee RemarksDirectSell529202520.1668,5471,381,9084,324,219Form
21Burke, FredSee RemarksDirectSell529202520.16138,7052,796,2938,326,463Form
22Forbes, KendallSee RemarksDirectSell529202520.1664,9911,310,2194,110,745Form
23Bindley, Capital Partners I, Llc DirectSell529202520.16651,45413,133,31339,106,711Form
24Bindley, William E Bindley Capital Partners I, LLCSell529202520.163,508,90570,739,52552,240,023Form
25Salentine, Thomas J JR Bindley Capital Partners I, LLCSell529202520.163,508,90570,739,52552,240,023Form
26Ackerman, John Pharmacy Investors, LLCSell529202520.16813,31816,396,49112,108,540Form
27Ackerman, John Cardinal Equity Fund, L.P.Sell529202520.16270,9585,462,5134,033,996Form
28Morris, David KSee RemarksDirectSell529202520.16369,2127,443,3145,706,127Form
29Burke, FredSee RemarksDirectSell529202520.16747,10215,061,57611,122,756Form
30Forbes, KendallSee RemarksDirectSell529202520.16350,0587,057,1695,420,964Form
31Bindley, Capital Partners I, Llc DirectSell529202520.163,508,90570,739,52552,240,023Form

Investor Activity (13F)

Updated Nov 17, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Boone Capital Management LLC$23.8 Mil7.3%13New13F
Valiant Capital Management, L.P.$44.7 Mil3.5%28Hold13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Boone Capital Management LLC$23.8 Mil7.3%13New13F
Active Manager
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Valiant Capital Management, L.P.$44.7 Mil3.5%28Hold13F
Boone Capital Management LLC$23.8 Mil7.3%13New13F
Core Cache Last Updated: 11/16/2026